The Urea Cycle Disorders Treatment Global Market Report 2023, provides comprehensive information on the urea cycle disorders treatment market across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa for the 27 major global industries. The report covers a ten year historic period – 2010-2021, and a ten year forecast period – 2023-2032.
Learn More On The Urea Cycle Disorders Treatment Market’s Growth:
https://www.thebusinessresearchcompany.com/report/urea-cycle-disorders-treatment-global-market-report
The global urea cycle disorders treatment market is expected to grow from $1.23 billion in 2022 to $1.29 billion in 2023 at a compound annual growth rate (CAGR) of 4.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global urea cycle disorders treatment is expected to reach $1.50 billion in 2027 at a CAGR of 3.9%.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample_request?id=12237&type=smp
Product innovation has emerged as a key trend gaining popularity in the urea cycle disorder treatment market. Major companies operating in the urea cycle disorder treatment market are concentrating on creating innovative products to strengthen their position in the market. For instance, in September 2022, Medunik USA, a US-based pharmaceutical company, launched Pheburane oral pellets, a unique and flavor-masking formulation of sodium phenylbutyrate (NaPB) for the long-term management of certain urea cycle disorders. It is a prescription drug used in conjunction with a particular diet to treat urea cycle disorders (UCDs) in adults and children that involve carbamyl phosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinate synthetase (AS) deficiency. It is measured using a reusable, calibrated dosing spoon included in each package; unlike other forms of NaPB, it does not need to be mixed or taken orally. Pheburane can be consumed together with a snack or meal, or it can be sprinkled on a spoonful of apple sauce or carrot puree and taken with water, fruit juice, or protein-free infant formula.
The urea cycle disorders treatment market is segmented:
1) By Treatment: Amino Acid Supplements, Sodium Phenylbutyrate, Glycerol Phenylbutyrate, Sodium Benzoate, Other Treatments
2) By Enzyme Deficiency: Ornithine Transcarbamylase (OTC), Argininosuccinate Synthetase (AS), Arginase (AG), Argininosuccinate Lyase (AL), Carbamoyl Phosphate Synthase (CPS1)
3) By Route of Administration: Oral, Injectables
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
North America was the largest region in the urea cycle disorders treatment market in 2022.
The table of contents in TBRC’s urea cycle disorders treatment market report includes:
1. Executive Summary
2. Urea Cycle Disorders Treatment Market Characteristics
3. Urea Cycle Disorders Treatment Market Trends And Strategies
4. Urea Cycle Disorders Treatment Market - Macro Economic Scenario
5. Global Urea Cycle Disorders Treatment Historic Market Size and Growth, 2017 - 2022, Value ($ Billion)
...................................
32. Global Urea Cycle Disorders Treatment Market Competitive Benchmarking
33. Global Urea Cycle Disorders Treatment Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Urea Cycle Disorders Treatment Market
35. Urea Cycle Disorders Treatment Market Future Outlook and Potential Analysis
36. Appendix
Learn About Us:
The Business Research Company is a market intelligence firm that pioneers in market, company, and consumer research. TBRC’s specialist consultants are located globally and are experts in a wide range of industries that include healthcare, manufacturing, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries. Through the report businesses can gain a thorough understanding of the market’s size, growth rate, major drivers and leading players.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email:
[email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model